NCT03739619View on ClinicalTrials.gov

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

December 22, 2023

Study Completion Date

April 30, 2025

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin LymphomaClassical Hodgkin LymphomaHodgkin Lymphoma
Interventions
DRUG

Bendamustine

Given IV

DRUG

Gemcitabine

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (2)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER

NCT03739619 - Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter